High-Risk HCP

Our new HCP ELISA kits are specifically designed for the sensitive and reliable detection of PLBL2/PLDL2.

Key Features:

• based on a CHO antigen, expressed in HEK293 cells, to minimize potential cross-reactivity with other CHO HCPs and enhance specificity.
• built using polyclonal antibodies, carefully selected for their remarkable versatility and broad binding affinity, ensuring outstanding sensitivity.
• Limit of Detection: 0.015 ng/mL and Working Range: 0.078-5 ng/mL.

Using a protein-specific ELISA can streamline your drug development process in several ways:

• Faster Regulatory Approval: Precise assays for critical HCPs like PLBL2 ease regulatory reviews, reducing potential delays.
• Enhanced Process Optimization: Accurate early detection of PLBL2 aids in refining purification methods, saving time.
• Lower Clinical Trial Risks: Early minimization of PLBL2 levels reduces immunogenicity risks, improving trial success rates.
• Streamlined Documentation: Validated ELISA data supports regulatory submissions, simplifying compliance and boosting credibility.